Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. (Q37962416)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124940%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124940%20AND%20SRC:MED&resulttype=core&format=json

Krystallenia I Alexandraki

17 January 2020

author

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124940%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Gregory Kaltsas

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124940%20AND%20SRC:MED&resulttype=core&format=json

Krystallenia I Alexandraki

17 January 2020

series ordinal

1

object named as

Krystallenia I Alexandraki

1 reference

26 August 2017

2

Gregory Kaltsas

1 reference

26 August 2017

language of work or name

1 reference

29 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124940%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124940%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124940%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124940%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

40-52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124940%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12020-011-9562-2

17 January 2020

exact match

0 references

cites work

The functional characterization of normal and neoplastic human enterochromaffin cells

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

The diagnosis and medical management of advanced neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Therapeutic options for gastrointestinal carcinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Poorly-differentiated endocrine carcinomas of midgut and hindgut origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

A simplified prognostic system for resected pancreatic neuroendocrine neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Natural history of neuroendocrine enteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

A 5-decade analysis of 13,715 carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Signaling mechanisms in neuroendocrine tumors as targets for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Genetics of neuroendocrine and carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Activated Raf-1 causes growth arrest in human small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Hesperetin, a potential therapy for carcinoid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Paraneoplastic syndromes secondary to neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Tachykinins in endocrine tumors and the carcinoid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Nuclear imaging of neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

NANETS consensus guidelines for the diagnosis of neuroendocrine tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

90Y-edotreotide for metastatic carcinoid refractory to octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

The mTOR pathway: a new target in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Endocrine tumours of the gastrointestinal tract: Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Efficient in vivo microRNA targeting of liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9562-2

Neuroendocrine gastrointestinal tumors--a condensed overview of diagnosis and treatment

21 January 2018

1 reference

12 December 2020

Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.

1 reference

12 December 2020

Standard imaging techniques for neuroendocrine tumors

1 reference

12 December 2020

The therapeutic potential of microRNAs: disease modulators and drug targets.

1 reference

12 December 2020

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

12 December 2020

Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours

1 reference

12 December 2020

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

12 December 2020

Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: Why Such Guidelines and How We Went about It

1 reference

12 December 2020

Surgery for gastroenteropancreatic neuroendocrine tumors (GEPNETS).

1 reference

12 December 2020

BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide

1 reference

12 December 2020

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

1 reference

12 December 2020

Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors

1 reference

12 December 2020

Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas

1 reference

12 December 2020

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

1 reference

12 December 2020

Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy

1 reference

12 December 2020

High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss

1 reference

12 December 2020